PL434485A1 - Synergistyczna kompozycja fagów oraz sposób jej otrzymywania - Google Patents

Synergistyczna kompozycja fagów oraz sposób jej otrzymywania

Info

Publication number
PL434485A1
PL434485A1 PL434485A PL43448520A PL434485A1 PL 434485 A1 PL434485 A1 PL 434485A1 PL 434485 A PL434485 A PL 434485A PL 43448520 A PL43448520 A PL 43448520A PL 434485 A1 PL434485 A1 PL 434485A1
Authority
PL
Poland
Prior art keywords
bactericidal activity
composition
obtaining
synergistic
phages
Prior art date
Application number
PL434485A
Other languages
English (en)
Inventor
Jarosław DASTYCH
Ewelina A. WÓJCIK
Agnieszka MASZEWSKA
Małgorzata STAŃCZYK
Anna PĘKALA
Edyta ŚMIGIELSKA
Ewelina WOJDA
Joanna KAZIMIERCZAK
Arkadiusz GUZIŃSKI
Justyna ANDRYSIAK
Paulina WIGNER
Original Assignee
Proteon Pharmaceuticals Spółka Akcyjna
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Proteon Pharmaceuticals Spółka Akcyjna filed Critical Proteon Pharmaceuticals Spółka Akcyjna
Priority to PL434485A priority Critical patent/PL434485A1/pl
Priority to EP21762150.7A priority patent/EP4171597A1/en
Priority to US18/012,318 priority patent/US20240050498A1/en
Priority to KR1020237002238A priority patent/KR20230038491A/ko
Priority to BR112022026489A priority patent/BR112022026489A2/pt
Priority to IL299434A priority patent/IL299434A/en
Priority to CN202180052662.1A priority patent/CN116096868A/zh
Priority to CA3183521A priority patent/CA3183521A1/en
Priority to PCT/PL2021/050047 priority patent/WO2021262019A1/en
Priority to MX2023000208A priority patent/MX2023000208A/es
Publication of PL434485A1 publication Critical patent/PL434485A1/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
    • C12Q1/18—Testing for antimicrobial activity of a material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2795/00—Bacteriophages
    • C12N2795/00011—Details
    • C12N2795/00021—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2795/00—Bacteriophages
    • C12N2795/00011—Details
    • C12N2795/00032—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2795/00—Bacteriophages
    • C12N2795/00011—Details
    • C12N2795/00051—Methods of production or purification of viral material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Communicable Diseases (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

Przedmiotem zgłoszenia jest sposób otrzymywania synergistycznej kompozycji fagów, charakteryzujący się tym, że uzyskuje się co najmniej dwa różne szczepy fagowe specyficzne wobec tego samego szczepu bakterii, określa się aktywność bakteriobójczą każdego ze szczepów fagów osobno oraz aktywność bakteriobójczą ich mieszaniny wobec tego szczepu bakterii, porównuje się aktywność bakteriobójczą określoną dla każdego ze szczepów fagów stosowanych osobno z aktywnością bakteriobójczą określoną dla ich mieszaniny i w przypadku stwierdzenia, że aktywność bakteriobójcza mieszaniny jest wyższa od aktywności bakteriobójczej każdego z fagów stosowanych osobno uznaje się, że fagi te tworzą kompozycję energistyczną. Przedmiotem zgłoszenia jest również synergistyczna kompozycja fagów specyficznych wobec bakterii APEC oraz wybrany szczep bakteriofaga nadający się do zapobiegania lub zwalczania zakażeń szczepami APEC.
PL434485A 2020-06-26 2020-06-26 Synergistyczna kompozycja fagów oraz sposób jej otrzymywania PL434485A1 (pl)

Priority Applications (10)

Application Number Priority Date Filing Date Title
PL434485A PL434485A1 (pl) 2020-06-26 2020-06-26 Synergistyczna kompozycja fagów oraz sposób jej otrzymywania
EP21762150.7A EP4171597A1 (en) 2020-06-26 2021-06-28 Synergistic composition of phages and its formation method
US18/012,318 US20240050498A1 (en) 2020-06-26 2021-06-28 Synergistic composition of phages and its formation method
KR1020237002238A KR20230038491A (ko) 2020-06-26 2021-06-28 파지의 상승적 조성물 및 이의 형성 방법
BR112022026489A BR112022026489A2 (pt) 2020-06-26 2021-06-28 Composição sinergística de fagos e seu método de formação
IL299434A IL299434A (en) 2020-06-26 2021-06-28 Synergistic composition of phages and its formation method
CN202180052662.1A CN116096868A (zh) 2020-06-26 2021-06-28 噬菌体的协同组合物及其形成方法
CA3183521A CA3183521A1 (en) 2020-06-26 2021-06-28 Synergistic composition of phages and its formation method
PCT/PL2021/050047 WO2021262019A1 (en) 2020-06-26 2021-06-28 Synergistic composition of phages and its formation method
MX2023000208A MX2023000208A (es) 2020-06-26 2021-06-28 Composicion sinergica de fagos y su metodo de formacion.

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PL434485A PL434485A1 (pl) 2020-06-26 2020-06-26 Synergistyczna kompozycja fagów oraz sposób jej otrzymywania

Publications (1)

Publication Number Publication Date
PL434485A1 true PL434485A1 (pl) 2021-12-27

Family

ID=77519726

Family Applications (1)

Application Number Title Priority Date Filing Date
PL434485A PL434485A1 (pl) 2020-06-26 2020-06-26 Synergistyczna kompozycja fagów oraz sposób jej otrzymywania

Country Status (10)

Country Link
US (1) US20240050498A1 (pl)
EP (1) EP4171597A1 (pl)
KR (1) KR20230038491A (pl)
CN (1) CN116096868A (pl)
BR (1) BR112022026489A2 (pl)
CA (1) CA3183521A1 (pl)
IL (1) IL299434A (pl)
MX (1) MX2023000208A (pl)
PL (1) PL434485A1 (pl)
WO (1) WO2021262019A1 (pl)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025210382A1 (en) * 2024-04-03 2025-10-09 Phagelab Chile Spa Compositions for the treatment of avian pathogenic e. coli

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016118738A1 (en) * 2015-01-23 2016-07-28 Intralytix, Inc. Novel shigella bacteriophages and uses thereof
WO2017223101A1 (en) * 2016-06-22 2017-12-28 The United States Of America As Represented By The Secretary Of The Navy Bacteriophage compositions and methods of selection of components against specific bacteria
US11672839B2 (en) * 2016-12-05 2023-06-13 Technechnophage, Investigacao E Desenvolvimento Em Biotecnologia, Sa Bacteriophage compositions comprising respiratory antibacterial phages and methods of use thereof

Also Published As

Publication number Publication date
MX2023000208A (es) 2023-02-09
CA3183521A1 (en) 2021-12-30
IL299434A (en) 2023-02-01
WO2021262019A1 (en) 2021-12-30
US20240050498A1 (en) 2024-02-15
CN116096868A (zh) 2023-05-09
EP4171597A1 (en) 2023-05-03
BR112022026489A2 (pt) 2023-05-09
KR20230038491A (ko) 2023-03-20

Similar Documents

Publication Publication Date Title
PH12022550469A1 (en) Kras g12d inhibitors
MX2023012245A (es) Compuestos, composiciones y metodos para el tratamiento del cancer.
PH12021550187A1 (en) Pyrrolopyrimidine itk inhibitors
MY204496A (en) Polyethylene compositions and articles made therefrom
MX2010001666A (es) Composiciones y metodos para el tratamiento de semillas.
GB202108194D0 (en) Bacteriophage composition, bacteriostat, and use thereof
MX2021000842A (es) Composiciones para la agricultura y metodos relacionados.
SA520420460B1 (ar) مشتق حلقي مخلط جديد
PL434485A1 (pl) Synergistyczna kompozycja fagów oraz sposób jej otrzymywania
GB202304235D0 (en) Compositions, methods and uses
PH12020551100A1 (en) Bowel cleansing composition
MY191930A (en) Microbial lysozyme for use in the treatment of irritable bowel syndrome or inflammatory bowel disease
EA202090424A1 (ru) Бициклические ингибиторы гистондеацетилазы
PH12021550121A1 (en) Methods of treating hfpef employing dapagliflozin and compositions comprising the same
MX2020011853A (es) Composiciones prebioticas y metodos para mantener una microbiota cutanea saludable.
MX2019014815A (es) Composicion antimicrobiana que incluye un acido dihidroxamico y metodos de inhibicion del crecimiento microbiano que usan el mismo.
GB2626637B (en) Compositions, methods and uses
MX2022003814A (es) Compuestos antibacterianos de 4-quinolinona.
MX2022003816A (es) Compuestos antibacterianos.
GB2621686B (en) Compositions, and methods and uses relating thereto
IL320161A (en) Compounds, compositions and methods
GB202305630D0 (en) Compositions, methods and uses
NZ755501A (en) Substituted 3-dialkylaminomethyl-piperidin-4-yl-benzamides and methods of making and using same
MX2020002441A (es) Composiciones y metodos de uso de depuradores de gammacetoaldehido para tratar, prevenir o mejorar fibrosis del higado.
EP3429588A4 (en) AMID SULPHAMIDE DERIVATIVES, COMPOSITIONS AND USES ASSOCIATED WITH CXCR4 INHIBITION